Evidence map›Paper›PMID 40804290›Full record

ArticleNPJ precision oncology2025

Multigene germline and somatic testing for epithelial ovarian cancer in China.

Lei Li, Jianwei Zhang, Nan Song, Bao Sun, Depu Zhang, Yi Li, Yunong Gao, Kui Wu, Qingshui Li, Cong Lin and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lei Li *Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
Jianwei Zhang *HIM-BGI Omics Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, China.
Nan SongKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gynecology, Peking University Cancer Hospital & Institute, Beijing, China.
Bao SunBGI Genomics, BGI-Shenzhen, Shenzhen, China.
Depu ZhangDepartment of Gynecology Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
Yi LiGynecology Oncology Center, People's Hospital, Peking University, Beijing, China.
Yunong GaoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gynecology, Peking University Cancer Hospital & Institute, Beijing, China.
Kui WuHIM-BGI Omics Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, China.
Qingshui LiBGI Genomics, BGI-Shenzhen, Shenzhen, China.
Cong LinHIM-BGI Omics Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, China.
Heng CuiGynecology Oncology Center, People's Hospital, Peking University, Beijing, China.
Boyang CaoHIM-BGI Omics Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, China.
Lusheng WangHIM-BGI Omics Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, China.
Kang ShaoHIM-BGI Omics Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, China. shaokang@genomics.cn.
Yan YouDepartment of Pathology, Peking Union Medical College Hospital, Beijing, China.
Huanwen WuDepartment of Pathology, Peking Union Medical College Hospital, Beijing, China.
Jinghe LangDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
Ming WuDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China. wuming@pumch.cn.

Funding

Peking Union Medical College Hospital Talent Cultivation Program (Category D) UHB12577the CAMS Innovation Fund for Medical Sciences (CIFMS) 2024-I2M-C&T-B-029the Independent Research Fund of State Key Laboratory of Complex, Severe and Rare Diseases in Peking Union Medical College Hospita 2025-I-ZD-001 and 2025-O-ZD-003the Key Research Project of Beijing Natural Science Foundation Z220013the National High Level Hospital Clinical Research Funding 2022-PUMCH-B-083, 2022-PUMCH-C-010, 2022-PUMCH-C-022 and 2022-PUMCH-D-003
6 · The paper itself

Abstract

This study investigated BRCA1/2 and homologous recombination repair (HR) pathway gene variants in Chinese epithelial ovarian cancer (EOC) patients. Germline and somatic variants in 21 HR-related genes were analyzed in 229 patients using a 21-gene ovarian panel and in 141 patients using a 508-gene pan-cancer panel. BRCA1, BRCA2, and HR-related gene mutation rates were 17.9%, 3.5%, and 23.1%, respectively, with TP53 as the most frequent somatic mutation (66.4%). Combined germline and somatic BRCA1/2 mutation rates rose to 23.6 and 6.1%. Survival analysis (n = 200) demonstrated longer overall survival (OS) in patients carrying BRCA1/2 or HR mutations. Notably, strategies including likely pathogenic (LP) and variants of uncertain significance (VUS) showed improved OS, especially in BRCA2 and BRCA1/2 somatic carriers. These findings suggest that integrating germline, somatic, and VUS data enhances survival prediction and guides treatment decisions in Chinese EOC patients.

Identifiers

PMID40804290
PMCPMC12350605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.